Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308950 | 0.85 | KMT2A (0.75) | KMT2ATSHRALDH1A1ESR1HSD17B10 | |
| SCHEMBL6486327 | 0.85 | TSHR (0.52) | KMT2ATSHRALDH1A1ESR1HSD17B10 | |
| SCHEMBL1138721 | 0.85 | KMT2A (0.84) | KMT2ATSHRALDH1A1ESR1HSD17B10 | |
| SCHEMBL9744197 | 0.84 | KMT2A (0.82) | KMT2ATSHRALDH1A1ESR1HSD17B10 | |
| SCHEMBL4106959 | 0.82 | KMT2A (0.71) | KMT2ATSHRALDH1A1ESR1HSD17B10 | |
| SCHEMBL13110327 | 0.82 | KMT2A (1.00) | KMT2ATSHRALDH1A1ESR1HSD17B10 | |
| SCHEMBL9745635 | 0.81 | KMT2A (0.78) | KMT2ATSHRALDH1A1ESR1HSD17B10 | |
| SCHEMBL4625144 | 0.81 | KMT2A (0.61) | KMT2ATSHRALDH1A1ESR1HSD17B10 | |
| SCHEMBL9440018 | 0.80 | KMT2A (0.68) | KMT2ATSHRALDH1A1ESR1HSD17B10 | |
| SCHEMBL13110344 | 0.79 | GAA (0.73) | KMT2ATSHRALDH1A1ESR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149166-A1 | LOW-FLUIDITY PACKAGING ADHESIVE FILM SPECIALLY FOR HETEROJUNCTION SOLAR CELL ASSEMBLY AND PREPARATION METHOD FOR SAME | 浙江祥邦科技股份有限公司 | 2024-07-18 | — | — | WO | claimed |
| US-20210388150-A1 | A PROCESS FOR PRODUCING A POLYURETHANE ELASTOMER | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2021-12-16 | — | — | US | claimed |
| EP-3883982-A1 | A PROCESS FOR PRODUCING A POLYURETHANE ELASTOMER | Covestro Intellectual Property GmbH & Co. KG (DE) | 2021-09-29 | — | — | EP | claimed |
| US-6962763-B2 | Silver-free black-and-white thermographic materials | EASTMAN KODAK COMPANY (US) | 2005-11-08 | — | — | US | claimed |
| US-20050186520-A1 | SILVER-FREE BLACK-AND-WHITE THERMOGRAPHIC MATERIALS | EASTMAN KODAK COMPANY | 2005-08-25 | — | — | US | claimed |
| WO-2024149166-A1 | LOW-FLUIDITY PACKAGING ADHESIVE FILM SPECIALLY FOR HETEROJUNCTION SOLAR CELL ASSEMBLY AND PREPARATION METHOD FOR SAME | 浙江祥邦科技股份有限公司 | 2024-07-18 | — | — | WO | disclosed |
| US-20210388150-A1 | A PROCESS FOR PRODUCING A POLYURETHANE ELASTOMER | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2021-12-16 | — | — | US | disclosed |
| EP-3883982-A1 | A PROCESS FOR PRODUCING A POLYURETHANE ELASTOMER | Covestro Intellectual Property GmbH & Co. KG (DE) | 2021-09-29 | — | — | EP | disclosed |
| US-6962763-B2 | Silver-free black-and-white thermographic materials | EASTMAN KODAK COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050186520-A1 | SILVER-FREE BLACK-AND-WHITE THERMOGRAPHIC MATERIALS | EASTMAN KODAK COMPANY | 2005-08-25 | — | — | US | disclosed |
| EP-1404338-A1 | ADENOSINE ANALOGUES FOR THE TREATMENT OF THE INSULIN RESISTANCE SYNDROME AND DIABETES | Aventis Pharma Deutschland GmbH (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030176390-A1 | Methods of treating insulin resistance syndrome and diabetes | HERLING ANDREAS (DE) | 2003-09-18 | — | — | US | disclosed |
| US-20020099030-A1 | Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-25 | — | — | US | disclosed |
| EP-0880540-B1 | 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE | AVENTIS PHARMA INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6376472-B1 | N6-SUBSTITUTED ADENOSINES | AVENTIS PHARMACEUTICALS, INC. | 2002-04-23 | — | — | US | disclosed |
| US-6365597-B1 | FOR THERAPY OF ANDROGEN AND ESTROGEN MEDIATED DISORDERS, INCLUDING BENIGN PROSTATIC HYPERPLASIA, ANDROGEN MEDIATED PROSTATE CANCER, ESTROGEN MEDIATED BREAST CANCER AND ACNE | AVENTIS PHARMACEUTICALS INC. | 2002-04-02 | — | — | US | disclosed |
| WO-2000023447-A1 | ADENOSINE ANALOGUES HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC ANTILIPOLYTIC PROPERTIES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0912520-A4 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE POULENC RORER PHARMA (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0912520-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998001426-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176390-A1 | Methods of treating insulin resistance syndrome and diabetes | IAPP, GPR119, INSR | KMT2A 3621/4885TSHR 1927/4885ALDH1A1 1392/4885 |
| US-20020099030-A1 | Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties | HMGCR, TGFB1, APOB | KMT2A 2439/4885TSHR 4041/4885ALDH1A1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.